Total submissions: 5
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Michigan Medical Genetics Laboratories, |
RCV000210981 | SCV000267768 | uncertain significance | Breast-ovarian cancer, familial, susceptibility to, 2 | 2016-04-21 | criteria provided, single submitter | clinical testing | |
Department of Pathology and Molecular Medicine, |
RCV000496491 | SCV000588094 | uncertain significance | not specified | 2017-04-20 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV001022836 | SCV001184617 | uncertain significance | Hereditary cancer-predisposing syndrome | 2021-05-05 | criteria provided, single submitter | clinical testing | The p.E1550Q variant (also known as c.4648G>C), located in coding exon 10 of the BRCA2 gene, results from a G to C substitution at nucleotide position 4648. The glutamic acid at codon 1550 is replaced by glutamine, an amino acid with highly similar properties. This amino acid position is poorly conserved in available vertebrate species. In addition, this alteration is predicted to be tolerated by in silico analysis. Since supporting evidence is limited at this time, the clinical significance of this alteration remains unclear. |
Invitae | RCV001321133 | SCV001511951 | uncertain significance | Hereditary breast ovarian cancer syndrome | 2021-10-28 | criteria provided, single submitter | clinical testing | This missense change has been observed in individual(s) with clinical features of BRCA2-related conditions (PMID: 21520333). This variant is present in population databases (rs80358695, gnomAD 0.0009%). This sequence change replaces glutamic acid, which is acidic and polar, with glutamine, which is neutral and polar, at codon 1550 of the BRCA2 protein (p.Glu1550Gln). ClinVar contains an entry for this variant (Variation ID: 225743). In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is not expected to disrupt BRCA2 protein function. |
University of Washington Department of Laboratory Medicine, |
RCV001022836 | SCV003850684 | likely benign | Hereditary cancer-predisposing syndrome | 2023-03-23 | criteria provided, single submitter | curation | Missense variant in a coldspot region where missense variants are very unlikely to be pathogenic (PMID:31911673). |